Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma

Journal of the Canadian Urological Association

Volumn 1, Issue 2 SUPPL, 2007, Pages

  Furge, Kyle A ^a   Dykema, Karl ^a   Petillo, David ^a   Westphal, Michael ^a   Zhang, Zhongfa ^a   Kort, Eric J ^a   Teh, Bin Tean ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54249156858     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Eble JN, International Agency for Research on Cancer, World Health Organization, editors. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
2. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-3.
3. Alimov A, Kost-Alimova M, Liu J, et al. Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma. Oncogene 2000;19:1392-9.
4. Kenck C, Wilhelm M, Bugert P, et al. Mutation of the VHL gene is associated exclu-sively with the development of non-papillary renal cell carcinomas. J Pathol 1996;179:157-61.
5. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
6. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-onco-gene in papillary renal carcinomas. Oncogene 1999;18:2343-50.
7. Khoo SK, Kahnoski K, Sugimura J, et al. Inactivation of BHD in sporadic renal tumors. Cancer Res 2003;63:4583-7.
8. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dube syn-drome. Am J Surg Pathol 2002;26:1542-52.
9. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell can-cer. Nat Genet 2002;30:406-10.
10. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003;73:95-106.
11. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006;354:2463-72.
12. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. Nat Genet 2005;37:S31-7.
13. Boer JM, Huber WK, Sultmann H, et al. Identification and classification of differen-tially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001;11:1861-70.
14. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003;162:925-32.
15. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003;22:6810-8.
16. Young AN, Amin AB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-51.
17. Yang XJ, Sugimura J, Schafernak KT, et al. Classification of renal neoplasms based on molecular signatures. J Urol 2006;175:2302-6.
18. Chuang ST, Chu P, Sugimura J, et al. Overexpression of glutathione s-transferase alpha in clear cell renal cell carcinoma. Am J Clin Pathol 2005;123:421-9.
19. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol 2004;28:69-76.
20. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell car-cinoma. Cancer Res 2005;65:5628-37.
21. Gettman MT, Blute ML, Spotts B, et al. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001;91:354-61.
22. Moch H, Mihatsch MJ. Genetic progression of renal cell carcinoma. Virchows Arch 2002;441:320-7.
23. Moch H, Presti JC Jr, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996;56:27-30.
24. Crawley JJ, Furge KA. Identification of frequent cytogenetic aberrations in hepatocel-lular carcinoma using gene expression data. Genome Biol 2002; Epub 2002 Nov 25;3: RESEARCH0075.
25. Haddad R, Furge KA, Miller J, et al. Genomic profiling and cDNA microarray analysis of human colon adenocarcinoma and associated peritoneal metastasis reveals consis-tent cytogenetic and transcriptional aberrations associated with progression of multi-ple metastases. Appl Genomics Proteomics 2002;1:123-34.
26. Harding MA, Arden KC, Gildea JW, et al. Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic poten-tials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 2002;62:6981-9.
27. Hughes TR, Roberts CJ, Dai H, et al. Widespread aneuploidy revealed by DNA microar-ray expression profiling. Nat Genet 2000;25:333-7.
28. Phillips JL, Hayward SW, Wang Y, et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 2001;61:8143-9.
29. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
30. Furge KA, Lucas KA, Takahashi M, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004; 64:4117-21.
31. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and onco-genic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007;67:3171-6.
32. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2005;439:353-7.
33. Kenck C, Wilhelm M, Bugert P, et al. Mutation of the VHL gene is associated exclu-sively with the development of non-papillary renal cell carcinomas. J Pathol1996;179: 157-61.
34. Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307-11.
35. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowl-edge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
36. Gerritsen ME, Tomlinson JE, Zlot C, et al. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol2003;140:595-610.
37. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001;98:9754-9.
38. Zhao H, Ljungberg B, Grankvist K, et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 2006;3:e13.
39. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.